Skip to main content
SpringerLink
Log in

Abatacept good value for money in CCP-2-positive RA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate

  2. The study received grant/research support from Bristol-Myers Squibb.

Reference

  • Alemao E, et al. Cost Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive RA Adult Patients by Anti-Cyclic Citrullinated Peptide-Positive Subgroups. Internet Document : abstr. THU0341, 13 Jun 2015. Available from: URL: http://dx.doi/org/10.1136/annrheumdis-2015-eular.2077

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abatacept good value for money in CCP-2-positive RA. PharmacoEcon Outcomes News 732, 10 (2015). https://doi.org/10.1007/s40274-015-2276-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2276-6

Search

Navigation